Sad to hear the passing of #ChadwickBoseman . Another reminder of the INCREASING problem of young patients with colorectal cancer. Debate regarding screening age in asymptotic patients aside...in young patients WITH symptoms Colorectal ca should be in differential [thread]
Data by birth cohort
Incidence trends for rectal cancer by age
Most cancers in young patients are not explained by any KNOWN mutations. Also increasing incidence so what is the reason ?
Increasing incidence rates vary by region. Why? Many questions remain about this problem
Gut microbiome may be at play...diet mediated or antibiotic effects? Large scale Longitudinal studies evaluating the effect of microbiome in young patients and colorectal cancer carcinogensis are needed. A challenge to do but may be revealing.
Short #tweetorial on issues related to toxicity in oncology trials. How do we conclude Tx A is more/less toxic than Tx B? Room for improvement when you look at how we collect and report toxicity. Vital for both therapy escalation and de-escalation trials [Thread]
Do we consistently grade events? Answer is no for retrospective and even prospectively this is a challenge with CTCAE. High grade events also require adjudication and attribution which is inherently a challenge. Nice study here pubmed.ncbi.nlm.nih.gov/32371073/@julian_hong@mpalta1098
We don't do well with chronicity of AE (CTCAE or PRO). Daily pads due to fecal incontinence for life (CTCAE grade 2) better or worse than grade 3 admit? One pt with a grade 3 for 2 weeks may be counted the same as another with the same AE for 6 months. "AUC" models needed
Nice to see PREOPANC published !ascopubs.org/doi/10.1200/JC… some thoughts. Resectability appears different in the paper than the protocol. (1)
Paper- “A tumor without arterial involvement and with venous involvement , 90° was considered resectable; a tumor with arterial involvement , 90° and/or venous involvement between 90° and 270° without occlusion was considered borderline resectable”
Protocol- “In this study, tumours with arterial abutment (less than 90° contact) and/or venous involvement (90°-270° contact but without vessel occlusion) are considered borderline resectable (table 1). Patients with clearly irresectable tumour are not eligible for this study.”